Last reviewed · How we verify
NCT05627089
Rheumatoid Arthritis and Myositis Cohort
trial in Rheumatoid Arthritis. Withdrawn.
1 January 2033
Quick facts
| Lead sponsor | Attune Health Research, Inc. |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 July 2023 |
| Primary completion | 1 January 2033 |
| Estimated completion | 1 January 2035 |
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
- Myositis — all drugs for Myositis →
Sponsor
Attune Health Research, Inc. — full company profile →
Who can join
18 and older, any sex, with Rheumatoid Arthritis or Myositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this research is to establish a well characterized clinical and longitudinal cohort for individuals with Rheumatoid Arthritis (RA) and Myositis to create a place to maintain blood, urine, stool specimens, excess tissue from procedures, and clinical data, which may be accessed for future research purposes. Specific research objectives of this cohort include: 1. Observe the response that immunosuppressive medications have on the immune cell population and cytokines in individuals with RA or Myositis. 2. Observe the role that the intestinal microbiome has on the immune cell population and cytokines in individuals with RA or Myositis. 3. Observe the connection between intestinal inflammation has on the immune cell population and cytokines in individuals with RA or Myositis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05627089
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other Attune Health Research, Inc. trials
Trials by the same sponsor.
- NCT04125459 — Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout · active not recruiting
- NCT03511625 — The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05627089 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Attune Health Research, Inc.
- Last refreshed: 30 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05627089.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing